An initiative of the Amyloidosis Research Consortium (ARC), ASPIRE brings together leading companies to tackle the most urgent challenges facing people living with amyloidosis, from improving diagnosis and expanding access to care, to addressing health disparities.

Founded in 2021, ASPIRE operates as a pre-competitive collaborative, uniting industry leaders around a shared purpose. The model is built on a simple belief: in rare disease, companies can and should work together on the problems no single organization can solve alone. ASPIRE aims to accelerate progress in the areas of diagnosis and care and to address health disparities through collaborative project design and shared resources, arriving at solutions that address common challenges and unmet need.